The public and commercial health care sectors are both committed to addressing the rising cost of health care through a shift in reimbursement models and Evolent offers a "comprehensive, turk-key solution" to help providers, Rhyee argued. In fact, the company is a "clear market leader" and remains underappreciated due to the "complexity of the business model."
"We believe the market under appreciates how uniquely positioned EVH is to capitalize on the paradigm shift to value-based healthcare," the analyst argued. "We view EVH as undervalued due to the company's potential leverage within the business model, increased TAM, and market demand by the investment community."
4 Keys To Success
Evolent's business model has considerable leverage and the company can penetrate its existing partnerships due to:
Finally, Evolent's management said in an investor day presentation that its total addressable market is as high as $150 billion, which marks an increase from a prior estimate of $45 billion. The analyst's 2018 revenue estimate implies the company has a "modest" penetration rate of 0.4 percent, which implies there is room for upside.
At time of publication, shares of Evolent were down 3.82 percent at $25.20.
Related Links: 150-Year-Old Aetna Pitches Itself As A Growth Company Senate Needs To Move Fast On Healthcare Before Overhauling Tax Codedate | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.